ISU to begin canine anticancer immunotherapeutic agent clinical trials

The school is teaming up with Canadian company NovaVive to conduct a clinical study

February 28, 2019

Iowa State University (ISU) College of Veterinary Medicine is starting a clinical study for a new canine anticancer immunotherapeutic.

Produced by NovaVive, the anticancer treatment, Immunocidin, has received regulatory approval in the U.S. and Canada to treat mammary tumors. The study will observe dogs with stage I or stage II splenic hemangiosarcoma (HSA) who have undergone a splenectomy to determine the effectiveness of Immunocidin in combination with doxorubicin chemotherapy. Sixty-six dogs will participate in the trial and survival times will be monitored.

“Treatment options and survival outcomes for canine HSA have remained essentially stagnant for the past two decades,” said Chad Johannes, DVM, DACVIM (SAIM, oncology). “Additional therapeutic options for HSA are needed and we look forward to learning more about how immune stimulation via Immunocidin may play a role in improving outcomes for dogs.”

Ten oncology clinics will participate in the trial. To find one, visit bit.ly/2D56wBv[1] and enter AAHSD004874 in the keyword search.

Endnotes:
  1. bit.ly/2D56wBv: http://bit.ly/2D56wBv

Source URL: https://www.veterinarypracticenews.com/isu-to-begin-anticancer-immunotherapeutic-agent-clinical-trials/